The naive question: if a drug that mimics one gut hormone already helps people lose weight, why build one that mimics two or three? Because the body doesn't regulate metabolism with a single switch — it uses a panel of them, and the 2022 patent record is full of single molecules engineered to push several of those switches at once.

Think of it like adjusting a room's comfort with one dial versus three. GLP-1 alone is the temperature dial. Add GIP and you're also controlling humidity; add glucagon and you're managing airflow. Each hormone receptor is a separate control, and the filings describe single molecules wired to turn several at once.

“A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.”— U.S. Patent No. 11,332,508 source

Hanmi Pharmaceutical's grant US11332508B2 is the clean three-receptor case, and the title is not subtle: a triple glucagon/GLP-1/GIP receptor agonist. Reading the actual claim shows how a "multi-receptor" molecule is defined in practice. It is not one fixed peptide but a roughly thirty-residue template in which each numbered position may be one of several listed amino acids — and several of those choices are non-natural residues such as aminoisobutyric acid (Aib) or α-methyl-glutamic acid. Those substitutions sit at the spots where the body's enzymes would normally cleave the peptide, so they are doing double duty: preserving the receptor fit while blunting the molecule's breakdown.

Crucially, the claim attaches numbers to the word "multi-receptor." It requires an in-vitro activity of about 0.1% or more at each of the three receptors compared with the native hormone, and dependent claims ratchet that up to 0.8%, 1%, even 4% at named pairings. That is the engineering definition of a balanced agonist: a way of excluding molecules that nominally touch three receptors but really only signal strongly at one. A further claim demands an increased in-vivo half-life versus any of the three native hormones — the property that turns a peptide that works in a dish into one that can be dosed on a practical schedule.

The two-button designs in the record make the same engineering visible from a different angle. Zealand Pharma's US11395847B2 covers acylated GLP-1/GLP-2 dual agonists, pairing GLP-1 with a different partner hormone. The word "acylated" is the tell: the claims attach a long fatty-acid chain — a 17- or 19-carbon di-acid, sometimes through a small spacer — to a specific lysine. That greasy tail binds albumin in the blood, creating a slow-release depot that extends the molecule's life. Publication US20220098265A1 describes glucagon/GLP-1 agonists specifically framed around obesity, another two-receptor combination staked out the same year.

Why does engaging several receptors interest so many filers? In plain terms, the receptors do not simply add up — the claims treat each as a distinct, separately specified target. GLP-1 signaling is associated with appetite and insulin handling; GIP and glucagon receptors govern different parts of energy and nutrient processing. A single peptide tuned to all of them is one molecule covering ground that previously took a combination. The patents report this as a design space, not a clinical result: they recite which receptors, which substituted positions, which potency thresholds, and which half-life requirement, and leave efficacy to be demonstrated elsewhere.

There is also a strategic reason the 2022 record is so dense. Because each molecule is claimed as a template of interchangeable residues plus an optional fatty anchor, a single inventive idea can be wrapped in a wide thicket of variants — different substitution menus, different acyl chains, different receptor combinations. That is why competing filers staked overlapping but distinct claims in the same window: the value is not just in one sequence but in the boundary you can draw around a whole family of them.

It is worth being precise about what "incretin" means here, since the word anchors the whole class. Incretins are gut hormones released after eating; GLP-1 and GIP are the two best known. Glucagon is not an incretin in the strict sense, which is why the triple-agonist title pairs "glucagon" with the two incretin receptors explicitly rather than lumping them together. The patents inherit that precision: each receptor is named separately in the claims, and the potency thresholds are stated per receptor, because the entire premise of the class is that these are distinct controls that happen to be engaged by one engineered molecule.

The structure of the claims also explains why this area produces so much litigation-grade overlap. When a molecule is claimed as a template — position 2 may be Aib or α-methyl-glutamic acid, position 10 may be one of several residues, and so on — two competing filings can describe overlapping but non-identical menus and still each capture real compounds. Add the optional acyl chain, whose length and spacer are themselves claimed variables, and the number of distinct-but-related molecules a single patent family can fence off becomes very large. That combinatorial breadth, visible directly in the 2022 claim language, is why filers raced to stake these templates rather than individual sequences.

So when you read about a powerful new weight or diabetes drug, the short version is that it is probably not mimicking one hormone. It is a multi-receptor agonist — a single engineered peptide whose numbered positions are tuned to several receptors and whose backbone and acyl tail are built to survive in the body — and the 2022 patent record is where that entire generation was being staked out.